Entering text into the input field will update the search result below

Merck announces positive mid-stage trial data for COVID-19 antiviral drug

Mar. 06, 2021 9:07 PM ETMerck & Co., Inc. (MRK) StockBy: Dulan Lokuwithana, SA News Editor18 Comments
  • Merck (NYSE:MRK) and Ridgeback Biotherapeutics have announced that molnupiravir (EIDD-2801/MK-4482), their investigational oral antiviral agent against COVID-19, managed to speed up the time for the infectious agent to become negative in COVID-19 patients.
  • The preliminary data from the Phase 2a study were

Recommended For You

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.